Healthcare
Cipla
CIPLA · NSE
Values as of FY2026, compiled 27 Oct 2026not live prices
Price — Last available / EOD
Not shown. LetsInvest has no licensed exchange feed, so no EOD close, chart or price-derived metric can be displayed — not even a stale one. Price-dependent metrics (P/E, P/B, dividend yield, drawdown, volatility, valuation bands) appear here only once a licensed vendor is connected; company fundamentals below are unaffected.
Snapshot
FY2026, compiled 27 Oct 2026
- Revenue
- ₹₹28,163Cr
- Net profit
- ₹₹3,862Cr
- ROE
- 11.2%
- Debt / equity
- 0.02×
- Revenue CAGR
- 7.4%
- Net profit CAGR
- 10.9%
FY2026, as reported
FY2026, as reported
Computed from the filings
Computed from the filings
Over FY2023–FY2026
n.a. over a loss or one-off base year
Fundamentals, as reported
Consolidated, annual
| ₹ crore | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Revenue | 22,753 | 25,774 | 27,548 | 28,163 |
| Operating profit | 5,027 | 6,291 | 7,128 | 5,883 |
| Other income | 293 | 552 | 862 | 606 |
| Interest | 110 | 90 | 62 | 54 |
| Depreciation | 1,172 | 1,051 | 1,107 | 1,211 |
| Profit before tax | 4,038 | 5,702 | 6,821 | 5,224 |
| Net profit | 2,833 | 4,154 | 5,269 | 3,862 |
| EPS (₹) | 34.71 | 51.05 | 65.28 | 48.02 |
| Dividend payout (%) | 24 | 25 | 25 | 27 |
Source & freshness
- Timeliness
- Static, verified · effective 2026-10-27
- Method
- Reported (compiled from filings); ratios below calculated by LetsInvest
- Note
- verified=false: cross-check against the annual report before relying. Coverage: the Nifty 50, from the Screener.in consolidated-page compilation (db/099).
Valuation
FY2026 per-share data
- EPS (₹)
- 48.02
- Dividend / share (₹)
- 12.97
FY2026, as reported
Computed: EPS × payout% ÷ 100
Per-share value is what the filings give without a market price: earnings and dividends per share above. The ratios that turn them into valuation — P/E, P/B, dividend yield, drawdown, volatility, valuation bands — are all computed locally and unit-tested, but every one of them needs a price or a close series as input, and no licensed feed supplies one yet. They render the moment an approved vendor feeds them EOD closes, each carrying its “Last available / EOD” date. Until then this page quotes no P/E rather than quoting someone else's without its date.
Quality
FY2026, period-end balance sheet
Method: calculated — the formulas are part of the page, not a vendor black box.
- ROE
- 11.2%
- ROCE
- 15.1%
- Debt / equity
- 0.02×
- Operating margin
- 20.9%
- Net margin
- 13.7%
- Net worth
- ₹₹34,432Cr
Net profit ÷ (equity capital + reserves)
(PBT + interest) ÷ (net worth + borrowings)
Borrowings ÷ net worth
Operating profit ÷ revenue
Net profit ÷ revenue
Equity capital + reserves
Ownership
Promoter holding for this company is not in the compilation yet. Shareholding data comes only from the sourced filings extract — it is never scraped live or inferred, so the section stays empty rather than approximate.
Risks & notes
Company-specific risk commentary ships with primary-source verification as coverage deepens. One structural note applies today: stored figures are filings compilations (verified=false), so a single-year jump or drop in the table — a demerger, a buyback, a one-off gain — is as-reported, not adjusted. Read the table's caption and source before drawing a conclusion from any one year.